What is CRON's 12-month stock price target?

Cronos Group Inc. Common Share (CRON) carries a 12-month consensus base price target of $3.2 (-3.9% from $3.33), with a bull-case target of $3.79 and a bear-case floor of $2.5.

Stock Ratings / Health Care / CRON / forecast

TRLV (56) RGC (38) TLRY (19) OBIO (34) ⌘ Pro Terminal →

Cronos Group Inc. Common Share (CRON) 12-Month Stock Forecast & Price Target Cone

Q: Is CRON stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates CRON D (Sell — SELL) with an RQD Confidence score of 49/100.

$3.33 +0.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.33

Cronos Group Inc. Common Share (CRON) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.22B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRON Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cronos Group Inc. Common Share (NASDAQ: CRON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $3.33 (+0.91% 1D, market cap $1.22B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CRON ranks #277 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRON compare to TRLV and RGC in the Health Care sector?

▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CRON carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of 42.8%, and ROIC of -4.5%. By comparison, TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) holds a D+ grade (56/100 RQD, P/E N/A, ROIC 12.8%, cap $1.98B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.33B). Among the 5-stock peer group, CRON leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRON?

▼

Per CRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001656472), Cronos Group Inc. Common Share generated $146.6M in revenue (+24.6% YoY), -$2.9M in net income, and $149.0K in free cash flow against $1.20B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.33 (-0.03%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRON)Realized 20D OHLCV Swing Band: ±5.3%

Deterministic 5-Pillar Attribution (49/100 Composite)

🔍 WHY CRON SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($149.0K FCF) & 42.8% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (22% of score)

20D Institutional Volume Accumulation (±5.3% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.20+2.5% Next Q

Q2 (-2Q)

Grade D$3.28+3% Next Q

Q3 (-1Q)

Grade D$3.38-1.5% Next Q

Current

Grade D$3.33-5.4% Hist 90D α

Trajectory: D (41) → D (49)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRON Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRON currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.30) and Max Pain ($3.50) forces dealer call-delta covering toward $3.79.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRON• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 49%NO 51%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CRON Position Size: $10,000

Shares at $3.33: 3003.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.50

$7,508

$-2,492 (-24.9%)

12M Consensus BaseTarget $3.20

$9,610

$-390 (-3.9%)

12M Bull Case BreakoutTarget $3.79

$11,381

+$1,381 (+13.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$3	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$4	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRON)

✓Walkthrough of CRON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.66%🛡️ HOLDING TREND SUPPORT

2026-11-03O $3.36H $3.36L $3.30C $3.33VOL 1.09M

RES: $3.43SUP: $3.28SMA50: $3.30SMA200: $2.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRON Butterfly Map → + Track CRON →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +24.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CRON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRON)

Health Care Rank #277 of 1015 ⚔️ TRLV vs CRON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRON vs. TRLV, RGC, TLRY, OBIO)

Industry: Medicinal Chemicals and Botanical Products (23 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cronos Group Inc. Common Share (CRON) ranks #277 by composite RQD confidence (49/100, grade D) and #331 by equity capitalization ($1.22B). Within this direct 5-issuer industry benchmark cohort, CRON leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with CRON at 49/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRON ACTIVE Cronos Group Inc. Common Share	D	49/100	—	42.8%	-4.5%	+0.91%	$1.22B	Benchmark Subject
TRLV Trulieve Cannabis Corp. Subordinate Voting Shares	D+	56/100	—	60.2%	12.8%	+7.98%	$1.98B	/trlv-vs-cron →
RGC Regencell Bioscience Holdings Limited	D-	38/100	—	—	—	-6.26%	$3.33B	/rgc-vs-cron →
TLRY Tilray Brands Inc.	E	19/100	—	28.4%	-3.9%	+0.79%	$373.9M	/tlry-vs-cron →
OBIO Orchestra BioMed Holdings Inc.	E	34/100	—	96.0%	-35.0%	-3.72%	$355.2M	/obio-vs-cron →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001656472 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cronos Group Inc. Common Share (CRON) reported GAAP revenue of $146.6M (+24.6% vs. FY2024 revenue of $117.6M , and +68.0% cumulative change since FY2023) , GAAP net income of -$2.9M, operating cash flow of $25.9M, and free cash flow of $149.0K (-97.7% YoY). On the balance sheet, CRON closed FY2025 with $1.20B in total assets against $0 in total debt (Altman Z-Score: 15.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$146.6M	-$2.9M	$25.9M	$149.0K	$1.20B	—
FY2024 (FY)	2024-12-31	$117.6M	$40.0M	$18.8M	$6.4M	$1.17B	—
FY2023 (FY)	2023-12-31	$87.2M	-$73.9M	-$42.8M	-$42.8M	—	—

3. CRON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CRON compare to TRLV and RGC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CRON?

Where is CRON trading relative to its 50-day, 200-day, and 52-week technical levels?

CRON last traded at $3.33 (+0.91% on volume of 1,010,096 shares), positioning the stock +0.91% above its 50-day simple moving average ($3.30) and +16.43% above its 200-day simple moving average ($2.86). Across its 52-week range of $2.28 to $3.61, CRON sits at the 78.9% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±5.3% ($3.15 to $3.51).

Direct Sub-Reports: CRON RQD Cockpit CRON 12M Forecast CRON Earnings & Move CRON Dividends & DRIP CRON Insiders & 13F CRON Whale Options CRON Profit Sankey CRON News & Why

ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ SEC XBRL & RQD VERIFIED

CRON — Cronos Group Inc. Common Share: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cronos Group Inc. Common Share (CRON) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $3.33 (+0.91% 1D, market capitalization $1.22B).

Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of -4.5%, gross margin of 42.8%, operating margin of -11.9%, and free cash flow yield of 0.01%.
Whale 13F & Options Flow (11/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 15.20, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cronos Group Inc. Common Share (CRON) is a NASDAQ-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry. The profile does not describe its specific products, customers, or revenue model. The company reported revenue of $146.6M for FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cronos Group Inc. Common Share (CRON) reported $146.6M in annual revenue (up from $117.6M in FY2024, +24.6% YoY) and -$2.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($87.2M revenue, -$73.9M net income) through FY2025, CRON scaled operating cash flow to $25.9M and free cash flow to $149.0K, backed by $1.20B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 49/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.01% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $2.28 – $3.61 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -11.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from source data. The only sector-level context available is the Health Care classification and the Medicinal Chemicals and Botanical Products industry, with a beta of 1.0 per the market data.

Key Question #1: Can CRON sustain or expand its -11.9% operating margin and -4.5% ROIC against Medicinal Chemicals and Botanical Products peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $146.6M and free cash flow of $149.0K, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CRON's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CRON Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cronos Group Inc. Common Share (CRON) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRON Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 1d ago

Cronos Group And 2 Other Canadian Penny Stocks To Own

Oil prices still reflect a war premium, with supply risks and depleted buffers keeping energy costs elevated. That kind of backdrop often punishes weaker balance sheets and rewards sturdier ones. For Canadian penny stock

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 4d ago

Altria’s Unusual Call Activity Offers a Lower-Risk Way to Wait for a Payoff

Altria owns 42.5% of Cronos Group and 8.1% of AB InBev, providing a lower-risk backdoor play. A 5.9% dividend yield pays you to wait, but longer-dated calls might be better than the unusually active Nov. 20 calls.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 5d ago

3 Canadian Penny Stocks With Up To 95% Below Fair Value

With the Bank of Canada lifting its key interest rate and signaling that borrowing costs could rise further, cash now earns more and weak balance sheets matter more. That puts financially healthier penny stocks in a very

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 6d ago

3 Canadian Penny Stocks With P E Under 18

AI is soaking up massive amounts of capital right now, with Meta’s recent US$25 billion share sale reportedly drawing demand about five times larger than the deal size. That kind of appetite for growth stories can pull a

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 8d ago

3 Canadian Penny Stocks With Net Margins Over 39%

Energy prices are back in the spotlight as the Bank of Canada signals a possible rate hike to keep fuel driven inflation from spilling into everything from groceries to rent. Higher borrowing costs can punish heavily ind

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 8d ago

Are Medical Stocks Lagging Cronos Group (CRON) This Year?

Here is how Cronos Group (CRON) and Amgen (AMGN) have performed compared to their sector so far this year.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 9d ago

3 Canadian Penny Stocks With Up To 67% Return On Equity

Rising global interest rates have made borrowing more expensive and pushed many investors toward safer balance sheets. That shift puts a spotlight on Canadian penny stocks that pair low share prices with relatively stron

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 10d ago

Cronos (CRON) Upgraded to Strong Buy: Here's What You Should Know

Cronos (CRON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRON Bull vs. Bear Conversation Board — What's Your Call at $3.33?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRON 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $3.89 (+17.9%)

📌 Pinned Debate

Forensic balance-sheet metrics (Altman Z 15.2, Piotroski F 6/9) and reported cash of $791.8M provide a solid financial cushion.

Here is why I am bullish on CRON here at $3.30: Forensic balance-sheet metrics (Altman Z 15.2, Piotroski F 6/9) and reported cash of $791.8M provide a solid financial cushion.. Compare CRON's -11.9% operating margin and -4.5% ROIC against the rest of Medicinal Chemicals and Botanical Products. As long as cash conversion holds up, dips toward $3.13 are getting bought.

CapAlloc_Nerd 🐂 BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medicinal Chemicals and Botanical Products. If gross margin (42.8%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $2.57 (-22.1%)

Spot @ $3.30

Negative ROIC of -4.5%, a 0.01% FCF yield, and insider conviction scored at 5/20 signal weak returns and limited insider support.

Careful chasing CRON at $3.30. Negative ROIC of -4.5%, a 0.01% FCF yield, and insider conviction scored at 5/20 signal weak returns and limited insider support.. Gross margin is 42.8%, but operating margin is -11.9%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.57 on multiple compression.